EMA delivers verdict on AstraZeneca: Safe and efficient

The European Medicines Agency (EMA), on Thursday delivered its verdict on the anti-covid19 vaccine, AstraZeneca. For the Agency, it is a “safe and effective” vaccine and “is not associated” with a higher risk of blood clots.

By making this announcement, particularly awaited by the fifteen European countries having suspended the administration of AstraZenaca for having associated it with cases of thrombosis (dangerous blood clots), the executive director of the EMA, Emer Cooke, has indicated that “its advantages (AstraZeneca) in the protection of people (…), with the associated risks of death and hospitalization, outweigh the possible risks”.

He added that the AEM “also concluded that the vaccine was not associated with an increase in the overall risk of thromboembolic events or blood clots”.